首页 > 市场调查报告书 > 製药

非专利药糖尿病生物製剂生技仿製药

市场调查报告书

商品编码

1983188

重组人胰岛素市场：依产品类型、品牌名称、通路及地区划分

Human Recombinant Insulin Market, By Product Type, By Brand, By Distribution Channel, By Geography

出版日期: 2026年02月12日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2026年重组人胰岛素市场规模估计为365亿美元，预计2033年将达到601亿美元。预计2026年至2033年，其复合年增长率将达7.4%。

分析范围		分析详情
基准年	2025	市场规模（2026 年）	365亿美元
效能数据	2020-2024	预测期	2026-2033
预测期（2026-2032 年）复合年增长率	7.40%	预计金额（2033 年）	601亿美元

重组人类胰岛素是一种合成胰岛素，它是利用重组DNA技术在大肠桿菌中培养胰岛素蛋白质而製成的。与其他类型的胰岛素（例如猪胰岛素或牛胰岛素）相比，重组人类胰岛素起效更快，免疫抗原性更低。人类胰岛素主要有两种剂型：短效（常规）和中效（NPH）。此外，预混合料人类胰岛素结合了两种胰岛素，其中一种用于全天控制血糖值，另一种用于餐后控制血糖值。由于全球范围内胰岛素生物相似药（后续产品）的开发，重组人类胰岛素市场正在蓬勃发展。

市场动态

久坐的生活方式、不健康的饮食习惯、肥胖、葡萄糖耐受不良、糖尿病家族病史以及胰岛素阻抗增加是全球人群中糖尿病的一些风险因素。此外，糖尿病患者人数的不断增加以及重组人类胰岛素研发投入的活性化，预计将在不久的将来推动重组人类胰岛素市场的成长。领先的生产商正在向市场推出创新且改良的重组人胰岛素，以满足日益增长的胰岛素需求。例如，2021年11月16日，製药公司Viatris Inc.和儿童公司Biocon Biologics Ltd.宣布在美国推出品牌相容生物类似药「SEMGLEE（甘精胰岛素-yfgn）注射液」和非品牌产品甘精胰岛素（甘精胰岛素-yfgn）注射液，旨在帮助1型糖尿病成人和成人儿童患者以及2型糖尿病这些药物有助于控制第1型糖尿病成人和儿童患者以及第2型糖尿病成人患者的高血糖。两种生物相似药均有管瓶和预填充注射笔两种剂型。

本报告的主要特点

本报告对全球重组人类胰岛素市场进行了详细分析，包括市场规模（以十亿美元计）和预测期（2026-2033 年）的复合年增长率，以 2025 年为基准年。
此外，它还确定了每个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
本文檔根据以下参数介绍了全球重组人胰岛素市场主要企业的概况：公司概况、产品系列、主要亮点、财务表现和策略。
本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
《全球重组人胰岛素市场》报告面向该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过分析全球重组人类胰岛素市场中使用的各种策略矩阵来促进决策。

北美洲
- 我们
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
非洲
- 南非
- 北非
- 中非

第八章竞争情势

Novo Nordisk A/S
Eli Lilly and Company
Sanofi SA
Julphar Gulf Pharmaceutical Industries
Biocon Limited
Bioton SA
Gan &Lee Pharmaceuticals, Ltd.
Zhuhai United Laboratories Co., Ltd.
Wanbang Biopharmaceuticals Co., Ltd.
Dongbao Enterprise Group Co., Ltd.

第九章分析师建议

机会
分析师意见
Coherent Opportunity Map (COM)

第十章：参考文献与分析方法

参考
分析方法
关于 Coherent Market Insights

简介目录

Product Code: CMI1797

Human Recombinant Insulin Market is estimated to be valued at USD 36.5 Bn in 2026 and is expected to reach USD 60.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 36.5 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.40%	2033 Value Projection:	USD 60.1 Bn

Recombinant human insulin is the synthetic insulin, developed using recombinant DNA technology by growing insulin proteins within Escherichia coli. Recombinant human insulin has a faster onset of action and lower immunogenicity than other types of insulin such as pork or beef insulin. Human insulin is available primarily in two forms: a short acting (regular) form and an intermediate acting (NPH) form. Moreover, the premixed human insulin is formed by combining two types of insulin, among which one is controls blood sugar level throughout the day, while second type of insulin helps to control blood sugar at meal times. Human recombinant insulin market is gaining traction due to development of biosimilars analogue of insulin, worldwide.

Market Dynamics

Sedentary and unhealthy lifestyle, unhealthy eating, obesity, impaired glucose tolerance, diabetes family history, and increased insulin resistance are some of the risk factors for developing diabetes among the global population. Moreover, increasing number of diabetic population, and growing research and development (R&D) studies in human recombinant insulin to introduce improved version of insulin in the market is expected to boost the growth of human recombinant insulin market in near future. Key manufactures are launching innovative and improved human recombinant insulin in the market to fulfill the increasing demand for insulin. For instance, on November 16, 2021, Viatris Inc., a pharmaceutical company and Biocon Biologics Ltd., a biopharmaceutical company announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilars products are available in vial and prefilled pen.

Key features of the study

This report provides an in-depth analysis of the global human recombinant insulin market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global human recombinant insulin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global human recombinant insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human recombinant insulin market

Market Segmentation

Product Type Insights (Revenue, USD Bn, 2026 - 2033)
- Rapid-Acting Human Insulin
- Short-Acting Human Insulin
- Intermediate-Acting Human Insulin
- Long-Acting Human Insulin
- Premixed Human Insulin
Brand Insights (Revenue, USD Bn, 2026 - 2033)
- Humalog
- Novolog
- Apidra
- Humulin R
- Novolin R
- Humulin N
- Novolin N
- Levemir
- Lantus
- Humalog Mix
- Novolog Mix
- Others
Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
Key Players Insights
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi S.A.
- Julphar Gulf Pharmaceutical Industries
- Biocon Limited
- Bioton S.A.
- Gan & Lee Pharmaceuticals, Ltd.
- Zhuhai United Laboratories Co., Ltd.
- Wanbang Biopharmaceuticals Co., Ltd.
- Dongbao Enterprise Group Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Global Human Recombinant Insulin Market, By Product Type
- Global Human Recombinant Insulin Market, By Brand
- Global Human Recombinant Insulin Market, By Distribution Channel
- Global Human Recombinant Insulin Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend

4. Global Human Recombinant Insulin Market, By Product Type, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Rapid-Acting Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Short-Acting Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Intermediate-Acting Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Long-Acting Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Premixed Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

5. Global Human Recombinant Insulin Market, By Brand, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Humalog
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Novolog
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Apidra
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Humulin R
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Novolin R
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Humulin N
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Novolin N
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Levemir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Lantus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Humalog Mix
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Novolog Mix
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

6. Global Human Recombinant Insulin Market, By Distribution Channel, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

7. Global Human Recombinant Insulin Market, By Region, 2020 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Julphar Gulf Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bioton S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gan & Lee Pharmaceuticals, Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zhuhai United Laboratories Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Wanbang Biopharmaceuticals Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Dongbao Enterprise Group Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

重组人胰岛素市场：依产品类型、品牌名称、通路及地区划分

Human Recombinant Insulin Market, By Product Type, By Brand, By Distribution Channel, By Geography

市场动态